Aug. 6 at 11:11 AM
$DTIL 10m os
06/08/2025 - 02:01 م
- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of complete cure
- Cohort 1, the lowest dose cohort (0.2 mg/kg) of ELIMINATE-B, established a safe and well-tolerated profile across multiple dose administrations for all patients
- PBGENE-HBV demonstrated substantial antiviral activity in all three patients in Cohort 1, with best responses achieving a 47-69% Hepatitis B surface antigen (HBsAg) reduction
- Durable HBsAg reduction of approximately 50% in patient 1 is observed 7 months after initial dose administration
- Dr. Mark Sulkowski, M.D., Professor of Medicine at the Johns Hopkins University School of Medicine and world-renowned expert in hepatitis B, expands role to Head Clinical Development Advisor
- Extended expected cash runway to the second half of 2027 providing more than two years of operating
